Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 18, 2014
Pharmacy Choice - News - Front Page Healthcare News - April 18, 2014

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/18/14 - Galectin Announces First Patient Dosed in Phase 1 Trial of GR-MD-02; Targeted Medical Pharma Completes Middle East Distribution Agreement
Peter G. Traber, President, Chief Executive Officer, and Chief Medical Officer of Galectin Therapeutics Inc. "These positive results have propelled the enrollment of the second cohort with strong participation across our clinical trial sites. In 2013, Galectin Therapeutics received Fast Track designation from the FDA for this clinical development..
4/18/14 - House speaker makes final push for Medicaid expansion with plan based on New Hampshire [Bangor Daily News, Maine :: ]
April 17 AUGUSTA, Maine The debate over Medicaid expansion has dominated the 126th Legislature, and it will continue to do so as the session winds down and lawmakers prepare to head back to their districts. Rather than simply expanding Medicaid permanently to 70,000 low-income Mainers as originally envisioned by the 2010 federal Affordable Care
4/17/14 - Actavis to Acquire Four Products from Akorn
Actavis plc, a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development for cash consideration. Actavis plc is a global, integrated specialty pharmaceutical company focused on...
4/17/14 - Actavis to Acquire Four Products from Akorn; Terms Undisclosed
Actavis plc, a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development for cash consideration. Actavis plc is a global, integrated specialty pharmaceutical company focused on...
4/17/14 - Akorn Completes Acquisition of Hi-Tech Pharmacal
Akorn, Inc., a niche pharmaceutical company, announced today that it has completed its previously announced acquisition of Hi-Tech Pharmacal Co., Inc. for $640 million in cash. The combination of Akorn and Hi-Tech will transform the Company into a larger, more diversified generic player. We are excited to announce that we have completed the acqu
4/17/14 - ALK announces FDA approval for Merck's ragweed sublingual allergy immunotherapy tablet RAGWITEK(r)
Licensed to Merck for North America by ALK, RAGWITEK (r) is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. Jens Bager, ALK's President and
4/17/14 - ALK announces FDA approval for Merck's ragweed sublingual allergy immunotherapy tablet RAGWITEK
Licensed to Merck for North America by ALK, RAGWITEK is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen. Jens Bager, ALK s President a
4/17/14 - Allen Technologies Deploys IPS Solution for Patient Education At Methodist Stone Oak Hospital
Allen Technologies announced today that Methodist Stone Oak Hospital, a nationally recognized patient-focused hospital in San Antonio, TX has selected and deployed the latest Interactive Patient System solution from Allen Technologies. "As we continue to build on our reputation as a health care facility where high-tech and high-touch come together
4/17/14 - Ansell Capital Corp. Announces Proposed Reverse Takeover Transaction With BriaCell Therapeutics Corp.
Ansell Capital Corp. is extremely pleased to announce that it has entered into a binding letter of intent for the arm's length acquisition of 100% of the issued and outstanding common shares of BriaCell Therapeutics Corp., a private cancer immunotherapy company incorporated under the laws of the State of Delaware with its head office in Los Angeles
4/17/14 - ApolloMed ACO Increases Patient Enrollment to 30,000 Medicare Beneficiaries and Number of Physicians to More Than 700 [Global Data Point]
ApolloMed ACO now has physicians and patients in Los Angeles County and Orange County in Southern California, Alameda County in the San Francisco Bay Area and Tulare County in Central California, as well as in Mississippi and Ohio.&# x0D;. "The goal of ApolloMed ACO is to improve the quality of care for Medicare fee-for-service patients," stated W
4/17/14 - ASTRO Applauds New CBO Estimate Demonstrating That Ending Self-Referral Abuse Would Save Medicare More Than $3 Billion
The Congressional Budget Office today released a new assessment of the significant costs associated with physician self-referral abuse, estimating that closing the self-referral law's loophole would save Medicare approximately $3.4 billion over a 10- year budget window. CBO's savings estimate comes on the heels of recent efforts by the Centers for.
4/17/14 - Benazir Income Support Programme to expand insurance coverage to its beneficiaries - Press Release issued by Benazir Income Support Programme - Sindh [Pakistan Press International]
Waseela-e-Sehet comprises of Group Life Insurance and Health Insurance coverage for the BISP beneficiary families. The pilot phase of Health Insurance was launched in Faisalabad district in April 2012 and approximately fifty nine thousand beneficiary families were enrolled in the programme while eight hospitals in the district were empanelled.
4/17/14 - Boston Heart Granted New York Laboratory Permit for Diagnostic Testing
Boston Heart Diagnostics Corporation, a pioneer in integrating next-generation diagnostics into personalized nutrition and lifestyle programs for patients with or at risk for heart disease, today announced that the company can serve patients from all 50 states now that it has successfully completed the New York State Department of Health clinical..
4/17/14 - Breathe Technologies, Inc. Announces FDA Clearance For NIOV System For Use With Compressed Gas
The previous four FDA clearances cover the use of the Breathe NIOV System with compressed oxygen for home and institutional use, and include invasive and noninvasive patient circuits. The Breathe NIOV System is the first and only FDA- cleared, wearable, ventilation system for people with respiratory insufficiency. The new FDA clearance for use of t
4/17/14 - Brightree Encourages Post-Acute Care Providers to Continue with ICD-10 Readiness Plans
By a News Reporter-Staff News Editor at Computer Weekly News Brightree, the leading provider of cloud-based clinical, billing and business management software solutions for the post-acute care industry, issued a response to the potential delay of ICD-10 for a year from October 1, 2014, to October 1, 2015. On March 10, 2014 Brightree announced its
4/17/14 - Bristol-Myers Squibb Reports Submission of New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat... [Health & Beauty Close - Up]
Bristol-Myers Squibb Company announced the submission of a new drug application on April 4, to the U.S. Food and Drug Administration for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-
4/17/14 - Canada : Modernizing Toronto East General Hospital [TendersInfo (India)]
Ontario is taking the next step to support new construction and renovations at Toronto East General Hospital so that local residents can access high-quality health care services. To support the planning and design of a new eight-storey, 380,000- square-foot tower at the hospital, Ontario is providing $19.6 million in new funding. This brings the to
4/17/14 - DIA 2014 50th Annual Meeting to Examine the Changing Landscape for Bioinnovation
DIA, in partnership with the Tufts Center for the Study of Drug Development, will convene health care experts for a forum called The Changing Landscape for Bioinnovation: The Emergence of Small Pharma, Strategic Alliances and Precision Medicine during DIA s 50th Annual Meeting at the San Diego Convention Center June 15 to 19. Smaller and s
4/17/14 - EMR/EHR-Friendly CloudVisit Simplifies Telemedicine [Global Data Point]
Designed to foster provider collaboration and reduce medical errors, CCR is an information technology standard for securely sharing and storing patient healthcare data. As an enhancement to their HIPAA-compliant telemedicine and telepsychiatry platforms, CloudVisit now facilitates data export in CCR format.&# x0D;. "Patient data portability is a m
4/17/14 - ETIAM to Exhibit at the New England Society for Healthcare Communications
At the upcoming New England Society for Healthcare communications, or NESHCO for short, ETIAM will demonstrate the practical uses of the ETIAM-Connect software, an integral and beneficial software that promotes the exchange and discussion between doctors and hospitals. ETIAM has been on the forefront of Medical Image Exchange software and telemedic
4/17/14 - Fact Sheet: Affordable Care Act by the Numbers
It is giving millions of middle class Americans the health care security they deserve, it is slowing the growth of health care costs and it has brought transparency and competition to the Health Insurance Marketplace. *3 million more people were enrolled in Medicaid and CHIP as of February, compared to before the Marketplaces opened. Medicaid and C
4/17/14 - FDA Announces Availability of Draft Guidance for Institutional Review Boards, Industry, Investigators and FDA Staff
WASHINGTON, April 17 The U.S. Department of Health and Human Services published the following notice in the Federal Register from the Food and Drug Administration:. Live Case Presentations During Investigational Device Exemption Clinical Trials; Draft Guidance for Institutional Review Boards, Industry, Investigators, and Food and Drug Administrat
4/17/14 - FDA Approves Merck's RAGWITEK? (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved RAGWITEK? Tablet for Sublingual Use. David Skoner, director, Division of Allergy and Immunology, Allegheny Health Network, and a clinical investigator in Merck's sublingual allergen immunotherapy tablet program.
4/17/14 - FDA Grants Approval to Merck's Grastek (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced... [Health & Beauty Close - Up]
FDA Grants Approval to Merck's Grastek Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Children and Adults. Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration has approved Grastek Tablet for Sublingual Use.
4/17/14 - First Round of Speak Exposure of Global Pharma Congress 2014
Topic: Action and prospects from regulator: Updates of Three-years Test Plan of QbD from FDA and EMA. FDAer responsible for premarket clearance of submissions by regulated industries as well as a member of FDA inspection team and participated in numerous on-site inspections. He also helps API and dosage form pharmaceutical companies in handling of
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool
An Overview of Complementary and Alternative Medicine
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415